The valuation trajectory of Doctolib between the first quarter of 2022 and the first quarter of 2026 represents a seminal case study in the maturation of the European HealthTech ecosystem. During this period, the company’s implied market value shifted from a primary funding peak of €5.8 Billion to a secondary transaction valuation of €3.6 Billion, marking a 40% decrease that has sparked extensive debate among industry analysts and institutional investors.

The European healthcare technology landscape has reached a definitive inflection point in 2026, transitioning from a period of speculative, venture-subsidised fragmentation into a disciplined era defined by industrial maturity and strategic consolidation. At the vanguard of this transformation is Doctolib, a platform that has successfully navigated the post-pandemic recalibration to emerge as the dominant digital health infrastructure provider across France, Germany, and Ital

Nelson Advisors thought leadership blog 'Healthcare.Digital' has featured in the Tony Blair Institute for Global Change publication 'The NHS at a Crossroads: The App That Can Transform Britain’s Health' highlighting the scale and importance of Doctolib in the French HealthTech market.

The IPO landscape for HealthTech startups in 2025 is likely to be dynamic, influenced by various factors such as market conditions, company performance and regulatory changes. While it's challenging to predict with certainty which specific companies will go public, the following six HealthTech startups have the potential to be among the IPO candidates: Omada Health, Hinge Health, Sword Health, Doctolib, Aledade, Quantum Health

Doctor-appointment booking app Doctolib has been valued at more than a billion dollars after raising new funding, adding to the surge of...